Category: PhRMA

US Democrats’ blockbuster budget bill could spell big changes for drug prices

drug pricing, Joe Biden, Market Access, Medicare, News, PhRMA, US Senate / August 5, 2022 August 5, 2022

The Inflation Reduction Act of 2022, a sweeping measure that now looks likely to be passed through budget reconciliation by Senate Democrats in the US, contains measures intended to greatly reduce US prescription drug prices — but the pharma lobby has reacted strongly against the bill, warning that it will lead to fewer innovative drugs …

US Democrats’ blockbuster budget bill could spell big changes for drug prices Read More »

Drug-industry survey blames insurer practices for barriers to care

BioPharma, biopharma nl, Daily, drug costs, drug pricing, health insurers, News, Pharma, PhRMA, Policy, Prior Authorization, Social Determinants, SYN, Top Story / June 6, 2022 June 6, 2022

Pharma companies often take the blame for high prescription costs. But a new, industry-sponsored survey shifts attention to insurance industry practices.

Top 5 takeaways from international hybrid and virtual meeting guidance for pharma

digital, EFPIA, IFPMA, Pharma, PhRMA, remote meetings, Sales and Marketing, Views & Analysis, Views and analysis, virtual meetings / May 25, 2022 May 25, 2022

The move to online international meetings has left pharma companies with uncertainty around contact compliance. But new joint guidance, from the IFPMA, EFPIA, and PhRMA, provides clarity. To say the world of work has changed is something of an understatement in the pharma and biopharma industry. Since COVID-19 reared its head more than two years …

Top 5 takeaways from international hybrid and virtual meeting guidance for pharma Read More »

Why the drug pricing debate is focused on insulin

diabetes, drug pricing, insulin, Market Access, Pharma, PhRMA, Views and analysis / April 13, 2022 April 13, 2022

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price is so controversial and whether this could be set to change. It has now been 100 years since the first patient with diabetes …

Why the drug pricing debate is focused on insulin Read More »

Supply chain middlemen ‘pocket half of US branded medicine spending’

medicines spending, News, pharmacy benefit manager, PhRMA, Sales and Marketing / January 13, 2022 January 13, 2022

In 2020, over half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders, overtaking the amount going to drug manufacturers for the first time, according to a new study. The report from Berkeley Research Group (BRG) – which was funded by the pharma industry trade group PhRMA – reveals …

Supply chain middlemen ‘pocket half of US branded medicine spending’ Read More »

Democrats agree last-ditch deal to save drug pricing plans

drug pricing, Financial, Joe Biden, Medicare, News, PhRMA, Sales and Marketing, US / November 4, 2021 November 4, 2021

Under fire for abandoning a plan to allow Medicare to negotiate drug pricing, Democrats in the Senate have reached an agreement that could see the policy reintroduced in the Biden administration’s ‘build back better’ spending proposals. A new stripped back proposal has won over rebel Democrats whose earlier opposition led the plan to be shelved, …

Democrats agree last-ditch deal to save drug pricing plans Read More »

Medicare drug price negotiation gets new life under Democrat-brokered deal

BioPharma, Centers for Medicaid and Medicare Services, Daily, drug prices, insulin, Legal, Legislation, Pharma, PhRMA, SYN, Top Story, Washington D.C., white house / November 3, 2021 November 3, 2021

Not all drugs will be subject to price negotiation under the revised legislation. But the agreement sets up a framework enabling Medicare to negotiate the prices of medicines that have been on the market for a long time, and also caps the monthly price of insulin, which has been a flashpoint of drug price debate.

New study ties pharma payments to prescription practices

Affordable Care Act, American Medical Association, Annals of Internal Medicine, BioPharma, biopharma nl, Centers for Medicaid and Medicare Services, Daily, Memorial Sloan Kettering Cancer Center, National Cancer Institute, News, Open Payments, PhRMA, Physicians, Policy, SYN, Top Story / November 24, 2020 November 24, 2020

Recent efforts to improve transparency haven’t made much of a difference, one author noted. But earlier reforms made a dent the “most egregious” practices.

Is COVID the Rx for the Pharmaceutical Industry’s Reputation?

Astra-Zeneca, BioNTech, Clinical Trials, COVID-19, COVID-19 Healthcare Marketing, COVIG-19 Alliance, Darlene Dobry, global public health crisis, Greedy pharma, GSK, Healthcare Advertising Agency, Healthcare Marketing Agency, healthcare reform, healthcare success, IFPMA, International Federation of Pharmaceutical Manufacturers and Associations, Johnson & Johnson, Kevzara, Medical Advertising Agency, Moderna, mRNA, mRNA vaccine, Novavax, Pharma indrustry, pharma marketing, pharma/device marketing and advertising, Pharmaceutical Marketing, Pharmaceutical Research and Manufacturers of America, PhRMA, Regeneron, remdesivir, Sanofi, Takeda, Thomas Cueni / August 26, 2020 August 26, 2020

Darlene Dobry, Strategic Advisor, Medical Devices and Pharmaceuticals As the COVID-19 pandemic continues to bring the world’s economies, healthcare systems, and communities to their knees, the Pharma industry appears to be the shining hope to help us return to a new normal. Could the industry’s response to this global public health crisis be the Rx …

Is COVID the Rx for the Pharmaceutical Industry’s Reputation? Read More »